Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Durect has concluded patient dosing in Bupivacaine Effectiveness and Safety in Saber trial (BESST) Phase III trial evaluating Posidur, a post-operative pain relief depot that uses Durect's patented Saber technology to deliver bupivacaine to provide up to three days of pain relief after surgery.
Subscribe to our email newsletter
The trial is to investigate the efficacy, effectiveness, safety and pharmacokinetics of Posidur in 305 patients undergoing a variety of general abdominal surgical procedures.
Durect expects to report top-line data from the BESST trial in the fourth quarter of 2011.
Durect has licensed Posidur to Hospira for commercialization in the US and Canada.